Sunday, July 6, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > Opinion > Pharma stocks see turbulence from US senate hearings

Pharma stocks see turbulence from US senate hearings

in Opinion
- Pharma stocks see turbulence from US senate hearings
Share on LinkedinShare on WhatsApp

As Big Pharma faces grilling, both parties will look to score political points.

US healthcare stocks are set for more turbulence after a rough start to 2019, as top executives from the industry prepare to be grilled by the Senate on high prescription drug costs.

The Senate Finance Committee hearing will only intensify the debate over healthcare costs, an issue which could also negatively impact the sector in the coming months.

With the 2020 US presidential race already on the horizon, drug companies will likely become political targets, causing unease for investors who hold stocks in much the same way as ahead of the last election in 2016.

Chief executives expected to appear at today’s hearing include those from AbbVie Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, Johnson & Johnson, Merck & Co Inc, Pfizer Inc and Sanofi SA.

Executives are strongly expected to point the finger for high drug prices elsewhere in the supply chain, such as at pharmacy benefit managers or insurance companies.

So far in 2019, the S&P 500 healthcare sector has climbed just 7% against a nearly 12% gain for the overall S&P 500, which is the benchmark index for large US companies. Pharma companies are up only 4%.

Although the Republican Party controls the committee running the hearing, the cost of drug pricing to consumers will almost certainly be highlighted by Democrats who took control of the House of Representatives in January.

Speaking to Reuters, Nicholas Colas, co-founder of DataTrek Research, recommended that investors underweight healthcare stocks because companies “are in the sights of both Democrat and Republican lawmakers.

“They are an easy target because the electorate really dislikes the American healthcare system,” Colas added.

Tags: CEOCEO NorthamHealthcarePaul Imisonpharma stocks

Related Posts

How a Data-Driven Mindset Powers McAfee’s Growth
Opinion

How a Data-Driven Mindset Powers McAfee’s Growth

Blackstone’s Jon Gray on Strategic Discipline, AI, and Entrepreneurial Leadership
Opinion

Blackstone’s Jon Gray on Strategic Discipline, AI, and Entrepreneurial Leadership

Canada, India move closer to trade deal
Opinion

Informing Strategic Planning Amid Tariff Uncertainty for Canadian Municipalities

A paradigm shift in supply chain operations: From agent-led to AI-led
Opinion

A paradigm shift in supply chain operations: From agent-led to AI-led

6 steps toward your retirement goals
Opinion

6 steps toward your retirement goals

Dollar continues record rally
Opinion

U.S. Economic Confidence Slightly Improved, Still Negative

How U.S. steel and aluminum tariffs would impact Canada’s economy
Opinion

The impact of US trade policy on jobs and inflation in Canada

Key Takeaways From Treasury’s Foreign Exchange Report
Opinion

Key Takeaways From Treasury’s Foreign Exchange Report

CVCA CEO Kim Furlong to step down
Opinion

What I’ve learned about building winning businesses

Inspiring vs. Infuriating: The Science Behind Great Leadership
Opinion

Inspiring vs. Infuriating: The Science Behind Great Leadership

No Result
View All Result

Recent Posts

  • What makes the Royal Edinburgh Military Tattoo so special?
  • Beyond the Machine: Why Human-Made Art Matters More in the Age of AI
  • 7 Benefits of High Intensity Interval Training
  • Paramount CEO explains why company paid Trump millions in 60 Minutes settlement
  • SAS CEO announces Air France–KLM to become majority owner

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.